Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

March 26, 2015
RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments

March 25, 2015
RegeneRx Receives Initial Payment for RGN-259 U.S. License to ReGenTree Joint Venture

March 9, 2015
RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Development of RGN-259/GBT-201

March 3, 2015
Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases

February 25, 2015
RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage

February 19, 2015
RegeneRx Updates Website